InvestSMART

Proteomics International Laboratories Ltd (ASX: PIQ) - Announcements

Current share price for PIQ : $0.185 0.01 (5.13%)+

ASX company news and announcements for Proteomics International Laboratories Ltd (PIQ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Proteomics International Laboratories Ltd (PIQ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Proteomics International Laboratories Ltd (PIQ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Proteomics International Laboratories Ltd (PIQ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$31 Amended Constitution 8 Nov 2024 3:21PM $0.700 $0.185 fallen by 73.57%
$31 Results of Meeting 8 Nov 2024 3:17PM $0.700 $0.185 fallen by 73.57%
$31 AGM Chairman's Address and Investor Presentation 8 Nov 2024 11:55AM $0.700 $0.185 fallen by 73.57%
$31 Board renewal update 30 Oct 2024 8:20AM $0.710 $0.185 fallen by 73.94%
$31 September 2024 Quarterly Activities Report and Appendix 4C 22 Oct 2024 8:09AM $0.780 $0.185 fallen by 76.28%
$31 Notification of cessation of securities - PIQ 14 Oct 2024 11:54AM $0.780 $0.185 fallen by 76.28%
$31 PromarkerD predicts kidney decline in T1D - study published 11 Oct 2024 8:23AM $0.790 $0.185 fallen by 76.58%
$31 Notice of Annual General Meeting/Proxy Form 9 Oct 2024 12:55PM $0.855 $0.185 fallen by 78.36%
$31 Esophageal cancer diagnostic delivers excellent results 23 Sep 2024 8:29AM $0.655 $0.185 fallen by 71.76%
$31 Initial Director's Interest Notice 20 Sep 2024 10:55AM $0.675 $0.185 fallen by 72.59%
$31 Investor Presentation 19 Sep 2024 8:25AM $0.565 $0.185 fallen by 67.26%
$31 Appointment of Director 16 Sep 2024 8:20AM $0.620 $0.185 fallen by 70.16%
$31 Update on commercialisation of PromarkerD in the USA 11 Sep 2024 8:16AM $0.870 $0.185 fallen by 78.74%
$31 Notification of cessation of securities - PIQ 27 Aug 2024 10:30AM $0.890 $0.185 fallen by 79.21%
$31 Groundbreaking results for type 1 diabetes and kidney health 23 Aug 2024 9:01AM $0.835 $0.185 fallen by 77.84%
$31 Annual Report to shareholders 23 Aug 2024 8:06AM $0.835 $0.185 fallen by 77.84%
$31 Corporate Governance Statement and Appendix 4G 23 Aug 2024 8:06AM $0.835 $0.185 fallen by 77.84%
$31 Preliminary Final Report 23 Aug 2024 8:06AM $0.835 $0.185 fallen by 77.84%
$31 Resignation of Director and Appendix 3Z 12 Aug 2024 5:38PM $0.865 $0.185 fallen by 78.61%
$31 June 2024 Quarterly Activities Report and Appendix 4C 30 Jul 2024 8:23AM $0.910 $0.185 fallen by 79.67%
$31 Notification of cessation of securities - PIQ 12 Jul 2024 1:53PM $1.010 $0.185 fallen by 81.68%
$31 Application for quotation of securities - PIQ 8 Jul 2024 10:59AM n/a $0.185 n/a
$31 Eurobio Scientific to sell PromarkerD DKD test in France 24 Jun 2024 8:15AM $0.885 $0.185 fallen by 79.10%
$31 Change of Director's Interest Notice 20 Jun 2024 2:29PM $0.883 $0.185 fallen by 79.04%
$31 Notification regarding unquoted securities - PIQ 17 Jun 2024 12:48PM $0.808 $0.185 fallen by 77.09%

126 - 150 of 686 results

Page 6 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.